Tom – Interview 14
Tom took part in a phase 2 trial of a new chemotherapy drug for lung cancer in 1993. Without the trial, the only other option at the time would have been palliative radiotherapy.
In 1993, Tom travelled to Saudi Arabia to work as an engineer. At a medical check it was discovered he had lung cancer. He returned home as soon as he could to Scotland, where he was told that surgery was not possible because he had some smaller cancerous nodes in his chest, as well as the main tumour. There was no known effective chemotherapy, and radiotherapy could not cure it. The only available option was palliative radiotherapy, to keep him comfortable, but he was not expected to live more than 9 months. Tom and his wife Helen felt very shocked and alone. There were several communication mix-ups over fixing appointments and sharing results between different members of staff which did not help the situation.
Eventually, about three months after diagnosis, Tom saw an oncologist who told him there was a phase 2 trial of a new chemotherapy drug (gemcitabine), for which he was eligible. This meant the trial was not a randomised trial comparing one treatment against another. Everyone in the trial got the new treatment for 6 months, to see whether it had any effect and what the side effects were. Tom felt he had no choice but to take the opportunity in the hope it would help him, and said yes immediately.
The small group of patients involved in the trial built up a strong supportive bond amongst themselves. Sadly, nearly all of them have since died, but in Tom’s case the chemotherapy seemed to get rid of the cancer in the smaller nodes, and the main tumour shrunk to a size which made it possible for him to have radical radiotherapy. He has had to retire because of the damage to his lungs, but 15 years on he is still alive and well, and able to tell the tale. He feels being offered the trial saved his life and gave him hope in an otherwise hopeless situation.
Tom has since become involved in a number of patient groups, and is the patient representative on the executive committee for the cancer clinical trials unit for Scotland. He is a strong supporter of the need for more medical research, including tests involving animals. He thinks it is easy for people to oppose it if they or their family have not faced a life-threatening illness. He feels the health service needs to do more to make sure people know what trials are available and have a chance to take part. He would advise anyone thinking about a trial to think about it positively, and bear in mind that you will be carefully monitored and you can withdraw at any stage if it is not working or the side effects are too great.